Advancing Skin Sensitization potency assessment for Essential Oils Comparative analysis of a component-based prediction model, GARDskin Dose-Response assay, and the Local Lymph Node Assay (LLNA) A new joint article by […]
Click image to view the Newsletter in browser. Text version: SenzaGen Newsletter Q2, 2026 The transition toward non‑animal methods As regulatory expectations evolve and industry demand for non‑animal testing grows, […]
Click image to view the Newsletter in browser. Text version: SenzaGen Newsletter Q1, 2026 SOT 2026: Advancing NAMs for skin and respiratory sensitization testing We had a fantastic time at […]
Advancing quantitative NAMs for skin sensitization risk assessment – Collaborative work within IDEA QRA-NAMs Working Group A new article published in Regulatory Toxicology and Pharmacology presents the outcomes of collaborative work within the […]
Click image to view the Newsletter in browser. Text version: SenzaGen Newsletter Q4, 2025 As 2025 draws to a close: This quarter caps a year of significant progress in advancing […]
Click image to view the Newsletter in browser. Safe dose levels for sensitizers, NESIL values for HRIPT, and PoD-based QRA Skin sensitization potency assessment has been in the spotlight at […]
Supporting industry decision-making and hypoallergenicity claims using an experimental setup combining GARD®skin Medical Device and Dose-Response protocols. Presented at 2025 Eurotox Download a copy in PDF Conclusion This case […]
